Search

Displaying results 2911 - 2920 of 10000 in total
  1. Drug

    Vayarin

    go.drugbank.com/drugs/DB09328
    Approved

    Approximately 60% of the users who completed 12 weeks of therapy reported subjective benefits from treatment. … This drug has also been used for management of hypertriglyceridemia [L1503].

    Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  2. Drug

    Pitolisant

    go.drugbank.com/drugs/DB11642
    ApprovedInvestigational

    [A32025] About 60-70% of patients with narcolepsy experience cataplexy, which is a sudden loss of muscle tone triggered by positive or negative emotions. … [A32022] Histaminergic neuron signalling in the brain plays a role in maintaining wakefulness; by blocking histamine autoreceptors, pitolisant enhances the activity of histaminergic neurons, as well as

    Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 Inducers
  3. Drug

    MK-4830

    go.drugbank.com/drugs/DB17454
    Investigational

    MK-4830 is a monoclonal antibody that targets the myeloid-specific immunoglobulin-like transcript (ILT) 4 receptor.

  4. Drug

    Acetate

    go.drugbank.com/drugs/DB14511
    Investigational

    Mixtures: VAMIN 14 IV AMINOASIT SOLÜSYONU, 500 ML, Virt-Bal DHA Plus
  5. Drug

    BMS-214662

    go.drugbank.com/drugs/DB12234
    Investigational

    Leukemia, and Adult Acute Promyelocytic Leukemia (M3), among others. … BMS-214662 has been used in trials studying the treatment of Childhood Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous

    Salts: BMS-214662 mesylate, BMS-214662 hydrochloride
  6. Drug

    CXA-10

    go.drugbank.com/drugs/DB15026
    Investigational

    CXA-10 is under investigation in clinical trial NCT03422510 (FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)).

    Synonyms: 10-nitro-9(E)-octadec-9-enoic acid
  7. Drug

    Gantenerumab

    go.drugbank.com/drugs/DB12034
    Investigational

    [A244705, A244710] These treatments include the related antibodies [aducanumab], which has been granted accelerated FDA approval, along with [bapineuzumab], [crenezumab], [donanemab], [lecanemab], and … As the classical view of AD pathology posits that Aβ accumulation triggers tau hyperphosphorylation and aggregation to form NFTs and cause neurodegeneration, large efforts have gone into developing treatments

  8. Drug

    Capmatinib

    go.drugbank.com/drugs/DB11791
    ApprovedInvestigational

    STAT3, PI3K/ATK, and RAS/MAPK. … [L13380] As this indication was granted under an accelerated approval, its continued approval is contingent upon verification of capmatinib's benefit in confirmatory trials.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  9. Drug

    Milatuzumab

    go.drugbank.com/drugs/DB12943
    Investigational

    Milatuzumab has been used in trials studying the treatment of Lupus Nephritis, Multiple Myeloma (MM), GVHD (Acute or Chronic), Myelodysplastic Syndrome, and Chronic Lymphocytic Leukemia, among others.

  10. Drug

    Esculin

    go.drugbank.com/drugs/DB13155
    Approved

    Esculin is found in barley. Vitamin C2 is generally considered a bioflavanoid, related to vitamin P esculin is a glucoside that naturally occurs in the horse chestnut (Aesculus hippocastanum), California Buckeye (Aesculus californica) an...